ArticleCell2021
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 348 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
348citing papers in PubMed, 1 pooled it
33.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
348 citing papers in PubMed, 1 synthesis or guideline pooled it, 539 citations in OpenAlex.
- Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.Reviews in medical virology · 2022Pooled it
- Circulating cholesterol fuels SARS-CoV-2 replication via ORF3a.EMBO reports · 2026Article
- Development of a recombinant single-cycle influenza viral vector as an intranasal vaccine against SARS-CoV-2.Scientific reports · 2026Article
- Combinatorial analysis of clinical and genomic data used to assess the association between SARS-CoV-2 mutations and disease severity.PNAS nexus · 2026Article
- From Bench to Insight: Rapid Pathogen Genomic Surveillance Workflow for SARS-CoV-2 and Emerging Pathogens.Genes · 2026Article
- Structural mimics of SARS-CoV-2.Infection · 2026Review
- Genomic surveillance of SARS-CoV-2 variants in hospitalized patients: a cohort study from the metropolitan area of valle de Aburrá, ColombiaBiomedica : revista del Instituto Nacional de Salud · 2026Article
- Pathological characteristics of SARS-CoV-2 variants and immune responses induced in a COVID-19 macaque model.Communications biology · 2026Article
- Back to the wildtype: SARS-CoV-2 evolution in critically ill patients with severe lung failure.Infection · 2026Article
- Slowdown of synonymous substitution rate preceding the emergence of multiple SARS-CoV-2 variants.Virus evolution · 2026Article
- Article
- Development of a Recombinant Single-Cycle Influenza Viral Vector as an Intranasal Vaccine against SARS-CoV-2 and SARS-like Betacoronaviruses.bioRxiv : the preprint server for biology · 2025Article
- AI designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains.Scientific reports · 2025Article
- The SARS-CoV-2 NSP4 T492I mutation promotes double-membrane vesicle formation to facilitate transmission.Virologica Sinica · 2025Article
- Article
- The Compensatory Effect of S375F on S371F Is Vital for Maintaining the Infectivity of SARS-CoV-2 Omicron Variants.Journal of medical virology · 2025Article
- NIEAs elicited by wild-type SARS-CoV-2 primary infection fail to enhance the infectivity of Omicron variants.Virology journal · 2025Article
- Epimaps of the SARS-CoV-2 Receptor-Binding Domain Mutational Landscape: Insights into Protein Stability, Epitope Prediction, and Antibody Binding.Biomolecules · 2025Article
- SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies.International journal of molecular sciences · 2025Review
- Review
288 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
46 authors at 6 institutions in 1 country.
Xianding DengDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA 94158, USA.
Miguel A Garcia-KnightDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Mir M KhalidDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institute of Virology, San Francisco, CA 94158, USA.
Venice ServellitaDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA 94158, USA.
Candace WangDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA 94158, USA.
Mary Kate MorrisCalifornia Department of Public Health, Richmond, CA 94804, USA.
Alicia Sotomayor-GonzálezDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA 94158, USA.
Dustin R GlasnerDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA 94158, USA.
Kevin R ReyesDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA 94158, USA.
Amelia S GliwaDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA 94158, USA.
Nikitha P ReddyDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA 94158, USA.
Claudia Sanchez San MartinDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA 94158, USA.
Scot FedermanLaboratory for Genomics Research, University of California, San Francisco, San Francisco, CA 94158, USA.
Jing ChengDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Joanna BalcerekDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA.
Jordan TaylorDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA.
Jessica A StreithorstDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA.
Steve MillerDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA.
Bharath SreekumarDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institute of Virology, San Francisco, CA 94158, USA.
Pei-Yi ChenDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institute of Virology, San Francisco, CA 94158, USA.
Ursula Schulze-GahmenDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institute of Virology, San Francisco, CA 94158, USA.
Taha Y TahaDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institute of Virology, San Francisco, CA 94158, USA.
Jennifer M HayashiDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institute of Virology, San Francisco, CA 94158, USA.
Camille R SimoneauDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institute of Virology, San Francisco, CA 94158, USA.
G Renuka KumarDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institute of Virology, San Francisco, CA 94158, USA.
Sarah McMahonDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institute of Virology, San Francisco, CA 94158, USA.
Peter V LidskyDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Yinghong XiaoDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Peera HemarajataLos Angeles County Public Health Laboratories, Downey, CA 90242, USA.
Nicole M GreenLos Angeles County Public Health Laboratories, Downey, CA 90242, USA.
Alex EspinosaCalifornia Department of Public Health, Richmond, CA 94804, USA.
Chantha KathCalifornia Department of Public Health, Richmond, CA 94804, USA.
Monica HawCalifornia Department of Public Health, Richmond, CA 94804, USA.
John BellCalifornia Department of Public Health, Richmond, CA 94804, USA.
Jill K HackerCalifornia Department of Public Health, Richmond, CA 94804, USA.
Carl HansonCalifornia Department of Public Health, Richmond, CA 94804, USA.
Debra A WadfordCalifornia Department of Public Health, Richmond, CA 94804, USA.
Carlos AnayaMonterey County Department of Public Health, Monterey, CA 93906, USA.
Donna FergusonMonterey County Department of Public Health, Monterey, CA 93906, USA.
Phillip A FrankinoInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA 94720, USA.
Haridha ShivramInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA 94720, USA.
Liana F LareauInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA 94720, USA; Department of Bioengineering, University of California, Berkeley, Berkeley, CA 94720, USA.
Stacia K WymanInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA 94720, USA.
Melanie OttDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institute of Virology, San Francisco, CA 94158, USA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA 94720, USA. Electronic address: melanie.ott@gladstone.ucsf.edu.
Raul AndinoDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: raul.andino@ucsf.edu.
Charles Y ChiuDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA 94158, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA 94720, USA. Electronic address: charles.chiu@ucsf.edu.
University of California, San Francisco · USGladstone Institutes · USCalifornia Department of Public Health · USInnovative Genomics Institute · USLos Angeles County Department of Public Health · USMonterey County Health Department · US
Funding
Pan-Genomic Approaches for Comprehensive Blood Screening of Novel or Emerging Infectious AgentsR01HL105704 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIU, CHARLES YEN · 2011 to 2020
$5.9MA new model of accelerated immune aging in HIV-infected drug usersDP1DA038043 · NIDA · J. DAVID GLADSTONE INSTITUTES · PI OTT, MELANIE MARIA · 2014 to 2019
$4.8MNEW HAMPSHIRE EPIDEMIOLOGY AND LABORATORY CAPACITYU50CI000498 · CI · NH STATE DEPT/HLTH STATISTICS/DATA MGMT · PI BEAN, CHRISTINE LOUISE · 2007 to 2011
$4.5MReal-Time Unbiased Pathogen Detection in Febrile Illnesses by Nanopore SequencingR33AI120977 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIU, CHARLES YEN · 2018 to 2020
$1.6MIdentification of diagnostic and prognostic host biomarkers of Zika virus infection by transcriptome profilingR21AI129455 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIU, CHARLES YEN · 2017 to 2018
$436kNCEZID CDC HHS U01 CK000539NCPDCID CDC HHS U50 CI000498NHLBI NIH HHS R01 HL105704NIAID NIH HHS R21 AI129455NIAID NIH HHS R33 AI120977NIDA NIH HHS DP1 DA038043
Abstract
We identified an emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the western United States. Named B.1.427/B.1.429 to denote its two lineages, the variant emerged in May 2020 and increased from 0% to >50% of sequenced cases from September 2020 to January 2021, showing 18.6%-24% increased transmissibility relative to wild-type circulating strains. The variant carries three mutations in the spike protein, including an L452R substitution. We found 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation common to variants B.1.1.7, B.1.351, and P.1. Antibody neutralization assays revealed 4.0- to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively. The increased prevalence of a more transmissible variant in California exhibiting decreased antibody neutralization warrants further investigation.
Indexed as
Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19HumansMutationSARS-CoV-2Spike Glycoprotein, CoronavirusWhole Genome SequencingAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirus20C/L452Rantibody neutralizationB.1.427/B.1.429COVID-19genomic epidemiologyL452R mutationmolecular datingpseudovirus infectivity studiesSARS-CoV-2spike proteinvariant of concernviral whole-genome sequencing
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.